Month: October 2023

Coca-Cola’s minimal impact of anti-obesity meds; counterfeit Ozempic and life-threatening seizures; first-graders in clinical obesity trials; $200B in obesity drug sales; and lower list prices.

Coca-Cola’s minimal impact of anti-obesity meds; counterfeit Ozempic and life-threatening seizures; first-graders in clinical obesity trials; $200B in obesity drug sales; and lower list prices.

October 29, 2023 No Comments

AT A GLANCE Coca-Cola CEO and chairman James Quincey said ‘…the company is currently seeing minimal impact from drugs like Ozempic and Wegovy…’, as per Eleanor Pringle at Fortune. The Austrian Federal Office for Safety in Health Care and the country’s criminal intelligence service reported ‘…Several people were hospitalized with life-threatening seizures and low blood sugar after taking counterfeit versions of the diabetes drug Ozempic.’ First graders with obesity,

Read More »
DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

October 23, 2023 No Comments

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results that showed the drug led

Read More »

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day.

October 15, 2023 No Comments

Hello all, It continues to be a fascinating, rapid and intense period of development in obesity and metabolic medicine. We learn something new virtually every week; we are very much looking forward to Obesity Week in Dallas, TX and the latest developments in evidence-based obesity science and treatments. In this Weekly Roundup, we have interesting articles including Novo Nordisk stopping their kidney outcomes

Read More »
Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

October 8, 2023 No Comments

Hello all, I hope everyone is having a wonderful weekend. I am back home after an intense week on the road, capped by a terrific two days at the ASMBS Weekend conference in New Orleans (where twenty30 health is a Bronze-level Corporate Council Member). It was an outstanding opportunity to connect with old friends and colleagues while making new ones

Read More »
Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

October 1, 2023 No Comments

Hello Friends, Welcome to October. It has been an extraordinarily busy period here at twenty30 health; amongst many other activities and initiatives, yours’ truly has been hitting the conference circuit of late, and have had the opportunity to attend excellent events at DHNY in New York and Health Evolution in Nashville. I also had the pleasure to be engage in

Read More »
Categories
Archives
Scroll to Top
Skip to content